- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Nanogen, Inc. (Nasdaq:NGEN), developer of advanced diagnostic products, announced today that Robert Saltmarsh, Vice President and Chief Financial Officer, will retire at the end of February 2008. Nick Venuto, currently the Executive Director of Finance, will become the Chief Financial Officer upon Mr. Saltmarsh's retirement. Mr. Saltmarsh will continue to consult with Nanogen, as needed, through the end of 2008.
We thank Rob for his outstanding service as our CFO and for the significant contributions he made to Nanogen during his tenure," said Howard Birndorf, Chairman and CEO. "As our executive director of finance, Nick Venuto has been responsible for financial operations and reporting at Nanogen for the last four years. Nick is also a CPA and has experience in public accounting as well as in industry. We are pleased to have someone of Nick's experience and capabilities step into the CFO role."
About Nanogen, Inc.
Nanogenís advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents and kits based on the Companyís proprietary probe technology branded as MGB Alertģ and Q-PCR Alert, and a line of rapid point-of-care diagnostic tests used in urgent care settings to aid in the diagnosis of heart failure conditions. Nanogenís ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications.
Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including those relating to the need for additional financing, reduction of expenses after restructuring activity, anticipated cash flow and profit, delisting from the NASDAQ Global Market, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Risk Factors" and elsewhere in Nanogenís Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
For more information, please click here
President & COO
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
European Technology Platform for Nanomedicine and ENATRANS European Consortium Launch the 2nd edition of the Nanomedicine Award: The Award to be presented at BIO-Europe conference in Munich, November 2015 July 30th, 2015
Take a trip through the brain July 30th, 2015
Sol-gel capacitor dielectric offers record-high energy storage July 30th, 2015
BESSTECH Names Doug Grose as Chief Technology Officer: Former GLOBALFOUNDRIES CEO to drive technology roadmap and strategic partnerships for emerging lithium-ion battery component company July 14th, 2015
A cool way to form 2-D conducting polymers using ice: POSTECH scientists develop breakthrough technique to easily optimize electrical properties of Polyaniline nanosheets to an unprecedented level in an environmental-friendly and inexpensive way July 7th, 2015